抗滋养层细胞表面抗原2靶向药:乳腺癌新的靶向治疗

Anti-trophoblast cell surface antigen 2 targeted drugs: a new targeted therapy for breast cancer

乳腺癌是常见的恶性肿瘤,具有显著异质性,经过标准治疗后大多患者预后良好,但仍有一些乳腺癌侵袭性高、预后差,特别是三阴性乳腺癌,需要开发出更新的治疗策略。抗滋养层细胞表面抗原2(Trop2)在乳腺癌中普遍呈表达率高,可成为具有潜力的治疗靶点,目前在药物研发和肿瘤治疗中也取得了一些进展,有些已经获批应用于临床,尤其是抗体药物偶联物类抗Trop2药物。本文将对Trop2的生物学功能、抗Trop2靶向药在乳腺癌的治疗最新进展等方面进行综述。

Breast cancer is a common malignant tumor with significant heterogeneity.After standard treatment,most patients have a good prognosis,but there are still some breast cancer cases with rapid progression and poor prognosis,especially triple negative breast cancer.Therefore,some new treatment strategies are required.Trophoblast cell surface antigen 2(Trop2)has a high expression rate in breast cancer and may become a potential therapeutic target.At present,there are some developments in drug research and tumor treatment,and some have been approved for clinical application,especially anti-Trop2 antibody–drug conjugate drugs.This article will review the biological function of Trop2 and the latest progress in the anti-Trop-2 targeted treatment of breast cancer.